The three CDK4/6is approved for use in clinical practice for first-line treatment of advanced estrogen receptor-positive, HER2-negative breast cancer together with endocrine therapy (palbociclib, ribociclib, and abemaciclib) are associated with an increase in progression-free survival [3,4,5]. This evidence concerns the gene ESR1 and breast carcinoma.